Pila Pharma (PILA.ST) Stock Analysis & AI Equity Report
Pila Pharma (PILA.ST) overview
Pila Pharma (PILA.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Pila Pharma reported revenue of SEK 1.1m and operating profit of SEK -7.9m; the year-end share price was 2.06 SEK and market capitalisation was SEK 71.3m. Pila Pharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Pila Pharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Pila Pharma
Pila Pharma is a Swedish biotechnology company developing TRPV1 inhibitors and antagonists for obesity, type 2 diabetes and selected inflammatory diseases. Its main asset is the XEN-D0501 drug candidate, supported by related patents and back-up compounds. The company also pursues development opportunities in erythromelalgia and other preclinical programs, with value driven by drug development and licensing.
Generate the Pila Pharma report
Pila Pharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Pila Pharma and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.